Skip to main content
. 2021 Jul 26;10(15):e020227. doi: 10.1161/JAHA.120.020227

Table 2.

Characteristics of G+LVH‐ Patients Versus Controls

Category

Mean (SD)

G+LVH‐

(n=45)

Control

(n‐26)

P Value
Age, y 37.2 (12.3) 38.9 (11.7) 0.788
No. of men, % 13 (28.9) 14 (50%) 0.085
BSA, m2 1.84 (0.23) 1.93 (0.21) 0.100
LA area indexed, cm2/m2 13.07 (2.2) 12.6 (1.8) 0.354
AMVLi, mm/m2 12.52 (2.1) 11.55 (1.6) 0.030*
≥2 LV crypts n (%) 13 (28.9) 0 (0) <0.005*
LVEDVi, mL/m2 73.7 (14.0) 78.0 (14.8) 0.222
LVESVi, mL/m2 21.0 (6.9) 26.7 (6.2) <0.005*
Ejection fraction (%) 71.9 (5.5) 65.8 (4.4) <0.005*
Massi, g/m2 45.4 (9.9) 52.6 (9.3) <0.005*
SV, mL 97.2 (21.2) 99.5 (25.5) 0.701
Visual perfusion defects n (%) 9 (20.0) 0 (0) 0.011*
Mean global stress MBF, mL/g per min 2.75 (0.71) 2.78 (0.9) 0.826
Mean MPR 2.77 (0.83) 3.24 (0.63) 0.009*
Mean rest MBF, mL/g per min 1.08 (0.37) 0.9 (0.23) 0.011*
Mean subendocardial MBF, mL/g per min 2.52 (0.82) 2.65 (0.69) 0.457
Mean subendocardial MPR 2.55 (0.75) 3.2 (0.65) <0.005*
Mean subepicardial MBF, mL/g per min 2.8 (0.73) 2.84 (0.59) 0.800
Mean subepicardial MPR 3.01 (0.96) 3.47 (0.75) 0.026*
Subendo:subepicardial MBF ratio 0.898 (0.17) 0.934 (0.14) 0.329
Subendo:subepicardial MPR ratio 0.87 (1.84) 0.93 (0.13) 0.092
Septal T1, ms 1025.6 (34.6) 1016.0 (31.7) 0.231
Septal T2, ms 49.2 (3.8) 47.7 (2.43) 0.041*
Septal ECV (%) 25.8 (2.4) 24.3 (2.6) 0.023*
MWT, mm 9.03 (1.95) 8.37 (1.2) 0.075
LGE present n (%) 8 (17.8) 0 (0%) 0.020*

AMVLi indicates indexed anterior mitral valve leaflet (length); BSA, body surface area; ECV, extracellular volume; G+LVH‐, genotype‐positive, left ventricular hypertrophy‐negative; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDVi, indexed left ventricular end‐diastolic volume; LVESVi, indexed left ventricular end‐systolic volume; Massi, indexed mass; MBF, myocardial blood flow; MPR, myocardial perfusion reserve; MWT, maximum wall thickness; and SV, stroke volume.

*

indicates significant P value <0.05.